文献速递传染病防控与疫情报告免疫规划

接种2剂JYNNEOS疫苗后的猴痘病毒感染——美国,2022年5月至2024年5月

Monkeypox Virus Infections After 2 Preexposure Doses of JYNNEOS Vaccine - United States, May 2022-May 2024.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2024-05-23

美国CDC在2022年5月至2024年5月期间收到27个辖区报告的271例完成2剂JYNNEOS疫苗接种后的猴痘病例,估计占完全接种者的<1%。与未接种者相比,突破性感染更多见于30-39岁非西班牙裔白人男性,与性伴侣数量增加相关,且病情较轻(p<0.001)。不同接种途径的感染时间间隔存在差异,提示免疫力未减弱。

要点

  • 完全接种JYNNEOS疫苗后仍可能发生猴痘突破性感染,估计占完全接种者的<1%。
  • 突破性感染病情较轻,更多见于30-39岁非西班牙裔白人男性且与性伴侣数量增加相关。
  • 皮内接种2剂者感染间隔中位363天,皮下接种者263天(p<0.001),提示免疫力未减弱。

核心结论

  • 2剂JYNNEOS疫苗可有效预防许多猴痘病例并减轻感染者症状严重程度,但完全接种者仍可能发生感染。
  • 完全接种者的突破性感染估计占完全接种者的<1%。
  • 与未接种者相比,完全接种者的感染更多见于30-39岁非西班牙裔白人男性,与性伴侣数量增加相关,且病情较轻(p<0.001)。
  • 不同接种途径的感染时间间隔差异提示免疫力未减弱;皮内接种2剂者感染间隔中位363天(IQR=221-444天),皮下接种2剂者中位263天(IQR=47-334天)(p<0.001)。

研究设计与样本

  • 美国CDC对2022年5月至2024年5月期间27个美国辖区报告的完全接种JYNNEOS疫苗后发生的猴痘病例进行描述性分析。

主要发现

  • 2022年5月至2024年5月,27个美国辖区向CDC报告了271例完全接种者的猴痘病例。
  • 这些报告感染估计发生在<1%的完全接种者中。
  • 与未接种者病例相比,完全接种者感染更可能发生于30-39岁非西班牙裔白人男性,与性伴侣数量增加相关,并导致病情较轻(p<0.001)。
  • 在数据完整的完全接种者感染中,接种后感染更常见于异源(皮下和皮内)接种(46%)或同源皮下接种(32%)后,而非同源皮内接种(22%)后。
  • 完全接种者中从接种到感染的时间间隔存在差异,提示免疫力未减弱。

临床怎么用

  • 建议接种JYNNEOS疫苗的人群应接种2剂,无论接种途径如何;目前不建议对受影响人群额外接种剂量。
  • 皮内接种是疫情高峰疫苗供应有限时的首选接种途径;本发现的意义尚不清楚,但这些数据应增强对皮内接种疫苗剂量有效性的信心。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Two doses of JYNNEOS vaccine are effective in preventing many mpox cases and can reduce the severity of symptoms in infected persons. However, infections among fully vaccinated persons can occur. During May 2022-May 2024, a total of 271 mpox cases among fully vaccinated persons were reported to CDC from 27 U.S. jurisdictions. These reported infections are estimated to have occurred in <1% of fully vaccinated persons. Compared with cases among unvaccinated persons, infections among fully vaccinated persons were more likely to occur among non-Hispanic White men aged 30-39 years, were associated with increased numbers of sexual partners, and resulted in less severe disease (p<0.001). Among infections in fully vaccinated persons with complete data, infections after vaccination were reported more commonly after receipt of heterologous (subcutaneous and intradermal) (46%) or homologous subcutaneous (32%) JYNNEOS vaccination than after homologous intradermal (22%) vaccination. Disparate time intervals from vaccination to infection among fully vaccinated persons suggest that immunity is not waning. The median interval between the second vaccine dose and illness onset was longer for cases among persons who had received 2 intradermal doses (median = 363 days; IQR = 221-444 days) compared with cases in persons who had received 2 subcutaneous doses (median = 263 days; IQR = 47-334 days) (p<0.001). The implications of this finding are not known; however, these data should increase confidence in the effectiveness of vaccine doses that were administered intradermally, the preferred method of administration during the peak of the outbreak when vaccine supply was limited. Persons recommended to receive the JYNNEOS vaccine should receive 2 doses, irrespective of the route of administration, and at this time, additional doses are not recommended for the affected population.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Guagliardo SAJ, Kracalik I, Carter RJ, et al. Monkeypox Virus Infections After 2 Preexposure Doses of JYNNEOS Vaccine - United States, May 2022-May 2024. MMWR Morb Mortal Wkly Rep. 2024. PMID: 38781111. doi:10.15585/mmwr.mm7320a3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。